Michael Day, MD
Family Medicine · Baton Rouge, LANPI 1790768729
Payments from drug & device makers
Across 212 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$482
- Novo Nordisk$338
- Boehringer Ingelheim$289
- Sanofi-aventis U.S. LLC$287
- AbbVie$285
- AstraZeneca$277
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $482 |
| Novo Nordisk | 20 | $338 |
| Boehringer Ingelheim | 17 | $289 |
| Sanofi-aventis U.S. LLC | 19 | $287 |
| AbbVie(2 entities) | 16 | $285 |
| AstraZeneca | 18 | $277 |
| Abbott | 10 | $209 |
| Lilly USA, LLC | 10 | $146 |
| Amarin Pharma, Inc. | 9 | $135 |
| Amgen | 8 | $133 |
| Pfizer | 8 | $121 |
| Genentech USA, Inc. | 8 | $116 |
| Merck | 8 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Johnson & Johnson | 7 | $103 |
| Exact Sciences | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $59 |
| Novartis | 3 | $49 |
| Eisai Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
How this compares
$3,541 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 30 | $33,150 |
| TradjentaLinagliptin | 18 | $21,298 |
| TrulicityDulaglutide | 16 | $20,004 |
| FarxigaDapagliflozin Propanediol | 14 | $19,117 |
| JanuviaSitagliptin Phosphate | 11 | $18,054 |
| MounjaroTirzepatide | 14 | $14,680 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $4,813 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,090 |
| Atorvastatin Calcium | 81 | $1,075 |
| Rosuvastatin Calcium | 42 | $621 |
| Metformin Hcl | 45 | $564 |
| Levothyroxine Sodium | 64 | $501 |
| Amlodipine Besylate | 47 | $445 |
| Tamsulosin Hcl | 16 | $426 |
| Testosterone Cypionate | 18 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $289 | $54,44848 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $146 | $34,68430 claims |
| AstraZenecaFarxiga | $277 | $19,11714 claims |
| MerckJanuvia | $105 | $18,05411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $50164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Baton Rouge
- Christine SmithBaton Rouge$185K
- Kevin DibenedettoBaton Rouge$80K
- Stan MaysBaton Rouge$15K
- Myles JaynesBaton Rouge$15K
- Yushen LeeBaton Rouge$14K
- Gerald BarberBaton Rouge$14K
- Vincent NguyenBaton Rouge$13K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.